Lv41
480 积分 2020-07-12 加入
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy
9小时前
已完结
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial
7个月前
已完结
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
7个月前
已完结
Digital image analysis improves precision of PD‐L1 scoring in cutaneous melanoma
10个月前
已完结
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
11个月前
已完结
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
11个月前
已完结
Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
11个月前
已完结
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
11个月前
已完结
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
11个月前
已完结
皖公网安备34019202002308
